HOUSE_OVERSIGHT_024016.jpg
2.78 MB
Extraction Summary
1
People
5
Organizations
3
Locations
1
Events
0
Relationships
3
Quotes
Document Information
Type:
Investment memorandum / private placement memorandum (page 5)
File Size:
2.78 MB
Summary
This document appears to be page 5 of a confidential investment memorandum for a fund named 'NLV-III' (likely New Leaf Ventures III). It outlines the investment thesis, citing a favorable regulatory environment due to increased FDA approvals and the FDASIA act of 2012, as well as favorable capital market dynamics caused by a contraction in venture capital fundraising which reduces competition for deals. The document bears a House Oversight Committee stamp, indicating it was part of a congressional investigation.
People (1)
| Name | Role | Context |
|---|---|---|
| The Fund Managers | Investment Managers |
Group managing the NLV-III fund, expressing beliefs about market conditions.
|
Organizations (5)
| Name | Type | Context |
|---|---|---|
| NLV-III |
The investment fund being discussed (likely New Leaf Ventures III).
|
|
| FDA |
U.S. Food and Drug Administration, discussed regarding regulatory approvals.
|
|
| Dow Jones |
Cited in footnote regarding market analysis.
|
|
| Fenwick & West |
Law firm cited in footnote regarding market analysis.
|
|
| House Oversight Committee |
Implied by the document stamp 'HOUSE_OVERSIGHT_024016'.
|
Timeline (1 events)
July 9, 2012
Food and Drug Administration Safety and Innovation Act (FDASIA) signed into law.
U.S.
U.S. Government
Key Quotes (3)
"The Fund Managers believe the massive expansion and integration of capabilities occurring in biology and information technology is enabling a period of innovation in healthcare that sets a uniquely positive environment for the investment of NLV-III."Source
HOUSE_OVERSIGHT_024016.jpg
Quote #1
"Capital Markets And Industry Dynamics Are Favorable For New Investments & Exits"Source
HOUSE_OVERSIGHT_024016.jpg
Quote #2
"Since the most recent peak in fundraising in 2008, it has been estimated that the life sciences venture capital fundraising has contracted by 68%, from $7.8 billion in 2008 to $2.5 billion in 2012"Source
HOUSE_OVERSIGHT_024016.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document